Harnessing the therapeutic potential of histotripsy focused ultrasound-induced immunogenic cancer cell death
利用组织解剖聚焦超声诱导免疫原性癌细胞死亡的治疗潜力
基本信息
- 批准号:10654919
- 负责人:
- 金额:$ 42.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAbscopal effectAntigen-Presenting CellsAntigensAttentionCD8-Positive T-LymphocytesCancer and SuicideCell CommunicationCell DeathCellsCessation of lifeClinicalColon CarcinomaDataDetectionDistantEventFocused UltrasoundFocused Ultrasound TherapyFoundationsFutureHeatingImmuneImmune checkpoint inhibitorImmune responseImmune systemImmunologic StimulationImmunologyImmunosuppressionImmunotherapeutic agentImmunotherapyInfiltrationInflammationInflammatoryInterventionInvestigationIonizing radiationLengthMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMechanicsMediatingMetabolicModalityPathway interactionsPatientsPhysiologic pulseProcessRadiationRoleSeriesSignal TransductionSiteT cell infiltrationT-Cell DepletionTechnologyTestingTherapeuticThermal Ablation TherapyTissuesTranslatingTumor AntigensUltrasonic waveWorkadaptive immune responseadaptive immunityanti-tumor immune responsecancer cellcancer immunotherapycarcinogenesiscell killingcell suicidecheckpoint inhibitionclinical practiceclinically relevantcytotoxicityimmunogenicimmunogenic cell deathimmunogenicityinhibitorinsightmelanomamillimetermouse modelmultidisciplinaryneoplastic cellnew technologypre-clinicalpreservationtraditional therapytumortumor ablation
项目摘要
PROJECT SUMMARY/ABSTRACT
Immunotherapy can be highly effective against cancers that elicit some recognition from the immune
system (e.g., melanoma), but it remains ineffectual against cancers that are largely invisible to immune detection
(e.g., pancreatic cancer). Advances in cancer immunotherapy will require interventions that can make cancers
more apparent to the immune system. A growing body of evidence suggests that focused ultrasound (FUS)
tumor ablation could be that intervention. By non-invasively disrupting cancer cells, thermal and mechanical
modes of FUS have been shown to trigger surprisingly potent immune responses against tumors. We have
found that histotripsy, a non-thermal mode of mechanical FUS, stimulates a powerful and systemic anti-tumor
immune response strong enough to cause abscopal regression of distant, non-ablated tumor sites – effects not
generally seen with traditional therapies like radiation or thermal ablation. Histotripsy is a technology that is
presently being introduced into clinical use; therefore, it will be imperative to understand the mechanistic
underpinnings of histotripsy immunostimulation. Our preliminary studies point to a stepwise series of events that
may explain this phenomenon. First, histotripsy causes the release of subcellular cancer cell antigens in a
manner that preserves their immunogenic integrity. Second, histotripsy induces cancer cells to undergo a
specific pathway of cellular suicide called necroptosis – a death pathway that attracts inflammation and immune
attention, effectively priming the immune system to recognize cancer antigens. What follows is a progressive
infiltration of CD8+ T cells into distant tumors that is accompanied by another pathway of cancer cell death called
ferroptosis – a death pathway recently discovered to be the critical mechanism by which immunotherapy-primed
CD8+ T cells kill cancer cells.
In this proposal, we will retrace these steps to understand how histotripsy exerts its unusually potent
immune effects. First, we will quantitatively fine-tune the parameters of histotripsy tissue cavitation that cause
maximally immunogenic tumor antigen release. Next, we will focus on the early induction of necroptosis to
determine if this is a necessary local precursor event on which later manifestations of histotripsy
immunostimulation depend. Then, we will examine the later process of CD8+ T cell-driven ferroptosis to
determine if this is the mechanism by which the distant, abscopal effects of histotripsy are mediated. Finally, we
will leverage mechanistic insights gained from these investigations to develop and test potential preclinical
strategies with which the effects of histotripsy on tumor antigen release, necroptosis, and ferroptosis could be
maximized for cancer immunotherapy. We have assembled a multidisciplinary team with expertise in FUS,
immunology and cancer immunotherapy to pursue this work, which promises to reveal insights and strategies to
bring the impact of cancer immunotherapy to a wider range of patients in need of cure.
项目概要/摘要
免疫疗法可以非常有效地对抗癌症,从而引起免疫系统的识别
系统(例如黑色素瘤),但它对免疫检测基本上不可见的癌症仍然无效
(例如,胰腺癌)癌症免疫疗法的进步将需要能够导致癌症的干预措施。
越来越多的证据表明聚焦超声(FUS)对免疫系统的影响更为明显。
肿瘤消融可能是通过非侵入性破坏癌细胞、热和机械干预。
FUS 模式已被证明能够引发令人惊讶的针对肿瘤的有效免疫反应。
发现组织解剖学(机械 FUS 的一种非热模式)可激发强大的系统性抗肿瘤作用
免疫反应足够强,足以引起远处未消融肿瘤部位的远隔消退——效果不
通常采用放射或热消融等传统疗法进行治疗。
目前正在投入临床使用,因此有必要了解其机制;
我们的初步研究指出了一系列逐步发生的事件
首先,组织解剖导致亚细胞癌细胞抗原的释放。
其次,组织切片诱导癌细胞经历免疫原性完整性。
细胞自杀的特定途径称为坏死性凋亡——一种吸引炎症和免疫的死亡途径
注意,有效启动免疫系统识别癌症抗原。接下来是一个渐进的过程。
CD8+ T 细胞浸润到远处的肿瘤,伴随着另一种癌细胞死亡途径,称为
铁死亡——最近发现的一种死亡途径是免疫治疗引发的关键机制
CD8+ T 细胞杀死癌细胞。
在本提案中,我们将回顾这些步骤,以了解组织解剖学如何发挥其异常强大的作用
首先,我们将定量微调引起组织空化的组织解剖参数。
接下来,我们将重点关注早期诱导坏死性凋亡。
确定这是否是一个必要的局部先兆事件,随后的组织解剖学表现
然后,我们将检查CD8+ T细胞驱动的铁死亡的后续过程。
确定这是否是组织解剖学远距离效应的介导机制。
将利用从这些研究中获得的机制见解来开发和测试潜在的临床前
组织解剖学对肿瘤抗原释放、坏死性凋亡和铁死亡的影响的策略
我们组建了一支具有 FUS 专业知识的多学科团队,
免疫学和癌症免疫治疗来开展这项工作,有望揭示一些见解和策略
将癌症免疫疗法的影响带给更广泛的需要治愈的患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Clifford Cho其他文献
Clifford Cho的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Clifford Cho', 18)}}的其他基金
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy
黑色素瘤过继性 T 细胞免疫疗法的临床前优化
- 批准号:
8764622 - 财政年份:2013
- 资助金额:
$ 42.03万 - 项目类别:
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy
重新设计肿瘤引流淋巴结以实现基于记忆 T 细胞的过继免疫治疗
- 批准号:
10617691 - 财政年份:2013
- 资助金额:
$ 42.03万 - 项目类别:
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy
重新设计肿瘤引流淋巴结以实现基于记忆 T 细胞的过继免疫治疗
- 批准号:
10049957 - 财政年份:2013
- 资助金额:
$ 42.03万 - 项目类别:
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy
黑色素瘤过继性 T 细胞免疫疗法的临床前优化
- 批准号:
8435605 - 财政年份:2013
- 资助金额:
$ 42.03万 - 项目类别:
Preclinical Optimization of Melanoma Adoptive T Cell Immunotherapy
黑色素瘤过继性 T 细胞免疫疗法的临床前优化
- 批准号:
8966625 - 财政年份:2013
- 资助金额:
$ 42.03万 - 项目类别:
Re-engineering the tumor draining lymph node to achieve memory T cell-based adoptive immunotherapy
重新设计肿瘤引流淋巴结以实现基于记忆 T 细胞的过继免疫治疗
- 批准号:
10403482 - 财政年份:2013
- 资助金额:
$ 42.03万 - 项目类别:
相似国自然基金
靶向VEGFR2增强放疗-免疫检查点抑制剂联合介导的远隔效应抑制肿瘤进展的机制研究
- 批准号:82360580
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
抑制巨噬细胞CD38活性减轻T细胞衰老进而增强放射-免疫远隔效应的作用与机制研究
- 批准号:82373021
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
慢性应激诱导YAP的O-GlcNAc修饰抑制宫颈癌放疗敏感性及远隔效应的机制和临床转化研究
- 批准号:82373207
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
共激活先天和适应性免疫的乏氧响应脂质体药物构建及其增强三阴乳腺癌立体定向放疗效果和远隔效应的研究
- 批准号:82372123
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
表面工程化纳米药物的免疫细胞增强转移性肺癌治疗中远隔效应的研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
相似海外基金
Program the Immune System against RAS-driven Cancer
对免疫系统进行编程以对抗 RAS 驱动的癌症
- 批准号:
10612257 - 财政年份:2023
- 资助金额:
$ 42.03万 - 项目类别:
Synergistic microglial activation and tumor cell killing for improved GBM response
协同小胶质细胞激活和肿瘤细胞杀伤可改善 GBM 反应
- 批准号:
10328499 - 财政年份:2021
- 资助金额:
$ 42.03万 - 项目类别:
Synergistic microglial activation and tumor cell killing for improved GBM response
协同小胶质细胞激活和肿瘤细胞杀伤可改善 GBM 反应
- 批准号:
10579973 - 财政年份:2021
- 资助金额:
$ 42.03万 - 项目类别:
Synergistic microglial activation and tumor cell killing for improved GBM response
协同小胶质细胞激活和肿瘤细胞杀伤可改善 GBM 反应
- 批准号:
10092562 - 财政年份:2021
- 资助金额:
$ 42.03万 - 项目类别:
Effects of FLASH Radiation on Cancer and the Immune Response
闪光辐射对癌症和免疫反应的影响
- 批准号:
10429937 - 财政年份:2019
- 资助金额:
$ 42.03万 - 项目类别: